Y-mAbs Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Y-mAbs Therapeutics Inc YMAB.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of nine analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -25 cents to -4 cents per share.

• Revenue rose 13.4% to $26.50 million from a year ago; analysts expected $27.29 million.

• Y-mAbs Therapeutics Inc's reported EPS for the quarter was a loss of 15 cents​.

• The company reported a quarterly loss of $6.79 million.

• Y-mAbs Therapeutics Inc shares had fallen by 33.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 9.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $20.50

This summary was machine generated from LSEG data March 4 at 03:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)